Search Within

Joachim Yahalom

  1. "Lymphoma"
Formats
  1. Meeting Abstract (95)
  2. Journal Article (88)
  3. Book Section (17)
  4. Research Letter (3)
  5. Conference Paper (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (205)
  2. Department of Medicine (205)
  3. Hematologic Malignancies, Division of (205)
  4. Lymphoma (205)
  5. Radiation Oncology, Department of (205)
  6. Survivorship Research (205)

More Groups

People
  1. Andrew Zelenetz (116)
  2. David Straus (82)
  3. Ariela Noy (71)
  4. Craig Moskowitz (71)
  5. Steven Horwitz (65)
  6. Maria Palomba (63)

More People

Years
  1. 2025 (2)
  2. 2024 (9)
  3. 2023 (20)
  4. 2022 (7)
  5. 2021 (12)
  6. 2020 (11)

More Years

Publications
  1. Blood (65)
  2. Hematological Oncology (15)
  3. Journal of Clinical Oncology (15)
  4. International Journal of Radiation Oncology, Biology, Physics (14)
  5. Journal of the National Comprehensive Cancer Network (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (73)
  2. Elsevier Inc. (25)
  3. Wiley Blackwell (18)
  4. American Society of Clinical Oncology (15)
  5. Harborside Press (14)
  6. John Wiley & Sons (9)

More Publishers

Results (205)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rosai-Dorfman disease - Utility of (18)F-FDG PET/CT for initial evaluation and follow-up
    Journal Article

    Mahajan, S.; Nakajima, R.; Yabe, M.; Dogan, A.; Ulaner, G. A.; Yahalom, J.; Noy, A.; Diamond, E. L.; Schöder, H.
    Clinical Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Early experience using radiotherapy as a salvage treatment for relapsed or refractory non-Hodgkin lymphomas following CD19 chimeric antigen receptor modified T-cell therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Dahi, P. B.; Sauter, C. S.; Scordo, M.; Batlevi, C. L.; Park, J. H.; Shah, G. L.; Giralt, S. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B.; Palomba, M. L.; DeSelm, C.; Batlevi, C. L.; Dahi, P. B.; Giralt, S. A.; Noy, A.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy
    Meeting Abstract

    Imber, B. S.; Palomba, M. L.; DeSelm, C.; Batlevi, C.; Dahi, P. B.; Giralt, S.; Noy, A. M.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save